
Dr Rathkopf on Niraparib Plus Abiraterone Acetate and Prednisone in HRR+ mCSPC
“This is an important study for this patient population. This is a patient population [that] tends to have worse prognosis due to their HRR alteration status." Dana E. Rathkopf, MD, a genitourinary medical oncologist and chair of the Research Council …